Stonepine Capital Management LLC Makes New $630,000 Investment in Kezar Life Sciences, Inc. (NASDAQ:KZR)

Stonepine Capital Management LLC purchased a new position in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 1,050,452 shares of the company’s stock, valued at approximately $630,000. Kezar Life Sciences makes up 0.6% of Stonepine Capital Management LLC’s holdings, making the stock its 20th largest holding. Stonepine Capital Management LLC owned approximately 1.44% of Kezar Life Sciences as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of KZR. Fidelis Capital Partners LLC bought a new position in Kezar Life Sciences during the first quarter worth $25,000. Mackenzie Financial Corp bought a new position in shares of Kezar Life Sciences during the 2nd quarter worth about $35,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Kezar Life Sciences in the 2nd quarter valued at about $63,000. Marquette Asset Management LLC bought a new stake in Kezar Life Sciences in the 1st quarter valued at about $114,000. Finally, BNP Paribas Financial Markets raised its stake in Kezar Life Sciences by 35.4% during the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock worth $247,000 after buying an additional 71,543 shares during the period. Institutional investors and hedge funds own 67.90% of the company’s stock.

Kezar Life Sciences Stock Up 42.2 %

Shares of NASDAQ KZR opened at $0.77 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.58 and a quick ratio of 9.58. Kezar Life Sciences, Inc. has a 1 year low of $0.52 and a 1 year high of $1.19. The stock has a market capitalization of $56.29 million, a P/E ratio of -0.55 and a beta of 0.20. The company has a 50-day moving average price of $0.60 and a 200-day moving average price of $0.70.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. On average, equities research analysts forecast that Kezar Life Sciences, Inc. will post -1.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Kezar Life Sciences in a report on Wednesday, August 14th.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.